Amprius Technologies Passes Military Performance Specification Nail Penetration Test with Unprecedented 390 Wh/kg Cell – Yahoo Finance
Amprius Cells Have Potential to Increase Energy Density and Reduce Overall Weight of Wearable Battery Cells for U.S. Army Soldiers
FREMONT, Calif., December 06, 2022–(BUSINESS WIRE)–Amprius Technologies, Inc. (“Amprius”) (NYSE: AMPX), a leader in ultra-high energy density lithium-ion batteries with its Silicon Nanowire Anode Platform, today announced that an independent third-party testing lab has validated Amprius’ 390 Wh/kg polymer electrolyte cell by successfully passing the nail penetration test per the requirements of section 4.7.4.4. of the MIL-PRF-32383 (Military Performance Specification).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005397/en/
Amprius Technologies Passes Military Performance Specification Nail Penetration Test with Unprecedented 390 Wh/kg Cell (Photo: Business Wire)
The test is used to determine the feasibility of a specific product in combat scenarios. Cells tested in accordance with 4.7.4.4. shall not burn or explode, and the external temperature of each test sample shall not be greater than 338 degrees Fahrenheit (170 degrees Celsius) when penetrated by sharp objects. When conducting the test, a 0.113-inch diameter stainless steel nail is driven through a fully charged cell at a prescribed speed. The cell is deemed to have passed if there is no smoke or flame following the nail penetration. The test video in real time, slow motion and infrared can be viewed at Amprius.com/technology/.
Amprius’ innovative polymer electrolyte prevents the penetrating nail from creating a low resistance short circuit, as indicated by the minimal increase in the cell temperature after penetration and only a small decrease in cell voltage. After nail penetration the cell is still functioning and providing power, a critical capability for soldier wearable batteries.
“As we work toward higher production capacity, the successful passing of this nail penetration test is a significant step in the progression of our technology and product development,” said Dr. Ionel Stefan, CTO of Amprius. “We have a unique opportunity to provide a significant energy density performance increase of nearly 100% – doubling the run-time for all mobile-powered devices without increasing the overall weight of wearable batteries for our U.S. Army soldiers.”
In October 2021, Amprius was awarded a contract by the U.S. Army to develop 100% silicon anode lithium-ion batteries. The 18-month rapid prototyping effort includes design, development, and validation of state-of-the-art, high energy density lithium-ion batteries to be used in various applications by the U.S. Army. As part of that program, Amprius is building and testing cells for use within U.S. Army soldiers’ central power source, the Conformal Wearable Battery (CWB). The CWB integrates into a soldier’s vest and powers critical communications and navigation equipment.
A purchase order for thirty battery packs has been placed by the U.S. Army for capability demonstration.
About Amprius Technologies, Inc.
Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries producing the industry’s highest energy density cells. The company’s corporate headquarters is in Fremont, California where it maintains an R&D lab and a pilot manufacturing facility for the fabrication of silicon nanowire anodes and cells.
For additional information, please visit amprius.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, each as amended, including Amprius’ management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Amprius’ partnership with BAE Systems and Amprius’ ability to produce its products at a commercial level. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Amprius’ management and are not predictions of actual performance. These forward-looking statements are not intended to serve as, and must not be relied upon by any investors as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond Amprius’ control. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks related to the rollout of Amprius’ business and the timing of expected business milestones; the effects of competition on Amprius’ business; supply shortages in the materials necessary for the production of Amprius’ products; the termination of government clean energy and electric vehicle incentives or the reduction in government spending on vehicles powered by battery technology; Amprius’ liquidity position; and delays in construction and operation of production facilities. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the “Risk Factors” section of Amprius’ current form on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 16, 2022, and other documents filed by Amprius from time to time with the SEC, all of which are available on the SEC’s website at www.sec.gov. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Amprius does not presently know or that Amprius currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Amprius’ expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements should not be relied upon as representing Amprius’ assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Except as required by law, Amprius specifically disclaims any obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005397/en/
Contacts
Investors
Cody Slach, Tom Colton
Gateway Group, Inc.
949-574-3860
IR@amprius.com
Media
Zach Kadletz, Brenlyn Motlagh
Gateway Group, Inc.
949-574-3860
Amprius@Gatewayir.com
Related Quotes
Earlier this year, in May, claims were made that Microsoft Corp co-founder Bill Gates owned the majority of America’s farmland. While that is false, with the billionaire amassing nearly 270,000 acres of farmland across the country, compared to 900 million total farm acres, a different billionaire privately owns 2.2 million acres, making him the largest landowner in the U.S. John Malone, the former CEO of Tele-Communications Inc., which AT&T Inc. purchased for more than $50 billion in 1999, has a
Wake up and smell the diesel.
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK). On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.
Chances are good you're ahead of 25% of your peers.
Nio will need to show record monthly vehicle deliveries in December by a large margin to hit even the low end of its prior estimates.
Reconnaissance Energy Africa Ltd. (the "Company" or "ReconAfrica") (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) announces a conference call for investors and analysts will be held on Thursday, December 8, 2022 at 11:00 am Eastern Time. Participants will include Scot Evans, Chief Executive Officer, Dr. James Granath, Chief Geoscientist, and Grayson Andersen, Head of Capital Markets.
Blackstone Inc Chief Executive Stephen Schwarzman said on Wednesday that redemptions in his firm's $69 billion non-traded real estate income trust (REIT) were driven by investors roiled by market volatility rather than dissatisfaction with the fund. Blackstone shares have lost 15% of their value since Dec. 1, when the New York-based firm disclosed it had for the first time limited redemptions from the REIT, which is marketed to high net-worth investors rather than institutional clients like pension funds and insurance firms.
This week has not been a fun time to own shares of Carnival (NYSE: CCL) (NYSE: CUK). Including today's 3.4% slide through 1 p.m. ET, Carnival stock has lost more than 10% of its value since the week began. On Tuesday, you see, investment banking heavyweight J.P. Morgan waded back into the cruise space with a trio of stock initiations.
Carvana shares spiraled Wednesday after the online car retailer’s biggest creditors reportedly signed an agreement to cooperate in potential restructuring negotiations as the company faces growing bankruptcy risk.
While speaking at Benzinga’s Future of Crypto event, investments in and by FTX were discussed as one of the biggest topics impacting the cryptocurrency sector. Kevin O’Leary was an investor in FTX and Anthony Scaramucci’s Skybridge Capital received an investment from FTX. Both shared their takeaways from the event of FTX and what happened with Sam Bankman-Fried. FTX Investments: Scaramucci said that many did not see warning signs with 25 of the greatest venture capitalists investing in FTX. Acco
Worried about the prospect of a recession coming next year? Well, that sounds like a mild scenario, if Michael Burry’s prognosis is anything to go by. The investor whose famous bet against the US housing market was documented in “The Big Short,” thinks a ‘multi-year recession’ is potentially in the cards – and one more severe than currently expected. This statement follows previous warnings regarding the economy, such as predicting last year that the ‘mother of all crashes’ is coming, while also
The rollercoaster ride continues in the stock market, and equities have been falling across the board this week. The S&P 500 is down 3.5%, and the Dow has lost some 870 points. The market drop was fueled by uncertainty; recent economic data has been unexpectedly positive, and it’s clouded the forecast for the Fed’s interest rate decision next week. The central bank’s twin mandates, to rein in inflation and to moderate unemployment, frequently run counter to each other, and with inflation running
Akeso Inc announced a collaboration and license agreement with Summit Therapeutics Inc (NASDAQ: SMMT) to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the U.S., Canada, Europe, and Japan. In addition, the company will co-brand the product in the license territories. Currently, Akeso is conducting a phase 3 trial of ivonescimab monotherapy versus pembrolizumab monotherapy as the first-line treatment for NSCLC patients wit
Will there be a new beginning?
Shares of many of America's largest banks are tumbling again on Tuesday after a period of outperformance that saw Goldman Sachs Group GS claw back practically all of its losses year-to-date.
After retirement you can start withdrawing the money you have accumulated over the years in your 401(k). However, a number of rules govern retirees' 401(k) distributions. For instance, in most cases to avoid penalties you have to wait until after … Continue reading → The post How Does a 401(k) Work When You Retire? appeared first on SmartAsset Blog.
Shares of United Natural Foods (NYSE: UNFI), the country's largest organic and natural food wholesaler, were pulling back today after the company issued a middling fiscal first-quarter earnings report. United Natural Foods said revenue in the quarter rose 7.6% to $7.53 billion, primarily driven by inflation and new business. The company also said it was implementing an industry-leading warehouse automation solution, which should help save on operating costs, and it also reduced its debt by $253 million by monetizing its accounts receivable.
Should you invest in a CD? The Fed's recent moves have sent interest rates—and APYs—higher.
Whether Santa eventually comes or not is still to be determined, with Mr. Claus perhaps postponing a decision until next Tuesday’s CPI release. Strategists led by Greg Boutle, head of U.S. equity and derivatives strategy, are expecting a capitulation event next year. “This would be a departure from the current bear market regime, which has been characterized by a grind lower in equities as P/E multiples have contracted,” they say.
Shares of MongoDB (NASDAQ: MDB) were flying higher today after the database software company posted strong results in its third-quarter earnings report. MongoDB, which specializes in NoSQL database software, trounced estimates in its latest update and even reported a surprise profit. Its cloud-based product, Atlas, again led the way with 61% growth and now makes up 63% of total revenue.